AbbVie
✦ StockVane Quant Insights how this is computed
- Mid-pack momentum — held if you own it, not a fresh buy.
- Signal has read HOLD for 3 months.
- Recent price momentum is +18.6% on average (3-month/1-year).
- Main-fund capital flow has been a net inflow over the last 45 sessions.
- Short interest has fallen to 0.9% of float.
- Analyst tilt is Buy.
- Price is above its 20-day average and above its 60-day average.
- The 20-day average is above the 60-day average, a short-term uptrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Price chart
Anonymous reader poll. Unscientific, not investment advice.
Performance
Key statistics
Price & volume
- Prev close
- 282.68
- Open
- 286.99
- Day range
- 285.00 - 290.98
- Avg price
- 288.83
- Volume
- 3.19M
- Turnover
- 921.99M
- Turnover ratei
- 0.18%
- Volume ratioi
- 0.58
- Amplitudei
- 2.12%
- 52-week rangei
- 188.25 - 291.40
Valuation
- P/Ei
- 121.98
- P/E (TTM)i
- 81.32
- P/Bi
- -85.70
- EPSi
- 2.36
- Book value / shi
- -3.36
- Net profit
- 4.17B
- Net assets
- -5.94B
Share structure
- Market cap
- 508.70B
- Float capi
- 507.80B
- Shares out
- 1.77B
- Float sharesi
- 1.76B
Dividend & listing
- Div yield (TTM)i
- 2.34%
- Dividend (TTM)
- 6.74
- Listing date
- 1970-01-01
1.2% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
+140.26M net over the window
Short interest
- Shares short
- 16.28M
- % of floati
- 0.92%
- Days to coveri
- 4.14
- As of
- 2026-09-30
Frequently asked questions
What is the current stock price of AbbVie (ABBV)?
AbbVie last traded at 287.87. The quote on this page refreshes every few seconds while US markets are open.
What is AbbVie's market cap?
About 508.70B.
What is the P/E ratio of AbbVie?
The trailing twelve-month P/E is 81.32, above its own 5-year average of 59.63 — toward the top of its historical range (74.66% percentile). See the Valuation tab for the full history.
Does AbbVie pay a dividend?
Yes. The trailing dividend yield is 2.34%. The 2025 payout was up 5.8% from 2024. See the Dividends tab for the full payment history.
Is AbbVie a buy according to analysts?
The consensus of 22 analysts is a Buy rating, with an average 12-month price target of 292.16, which implies 1.5% upside from the current price. This is not investment advice.
What is AbbVie's StockVane Quant Rating?
The StockVane Momentum strategy currently rates AbbVie a C (Hold). Mid-pack momentum — held if you own it, not a fresh buy. Not investment advice.
Quote time 2026-10-20 15:30:12 · For reference only, not investment advice and not tailored to your situation.
patent cliff fears priced in years ago and the new drugs stepped up more than skeptics expected. dividend yield here is still doing a lot of the work for the stock.